Bicyclic furanopyrimidine nucleoside analogues (BCNAs) have been previously reported as potent and selective antivaricella-zoster virus (VZV) inhibitors (McGuigan et al., 1999) .
Structure-activity relationship (SAR) studies on this class of compounds suggest that a specific requirement for displaying antiviral activity is a long lipophilic side chain on the furanopyrimidine moiety, as demonstrated in the lead series [1] (Figure 1) , where the optimal antiviral activity resides in the chain length equal to C 8 -C 10 .
After the discovery of the lead series [1], a large number of derivatives has been synthesized in order to study the requirements needed to display biological activity. Following these SAR studies, we discovered a great enhancement of potency associated with the introduction of a phenyl ring in the side chain [2] (Figure 1) . Indeed, the most active compound reported so far is the ppentylphenyl derivative with an EC 50 equal to 0.0003 µM versus VZV strain OKA and entire specificity versus VZV (McGuigan et al., 2000) .
Little is known about the mechanism of action of this new class of potent and specific antivirals against VZV, however the lack of activity of all the bicyclic furanopyrimidine nucleosides against thymidine kinase (TK)-deficient VZV strains suggests a viral TK-mediated phosphorylation as an essential activation step (Sienaert et al., 2002) .
Although an extensive study has been carried out in order to investigate the effect of modifications on the base, Bicyclic nucleoside inhibitors of varicella-zoster virus modified on the sugar moiety: 3′ and 5′ derivatives Introduction Bicyclic furanopyrimidine nucleoside analogues (BCNAs) have been previously reported as potent and selective anti-varicella-zoster virus (VZV) agents. Few modifications on the sugar moiety have been considered so far but some of them have shown interesting activity against human cytomegalovirus (HCMV) while losing activity against VZV. In addition, recent work has led to an entirely new series of anti-HCMV bicyclic furopyrimidine agents, acting through a non-nucleoside mechanism. In order to further investigate structure-activity relationship studies on the sugar moiety, some 3′-and 5′-chloro derivatives and 5′-deoxygenated derivatives have been synthe-sized. The lack of anti-VZV activity of the 5′-modified derivatives is further proof of a mechanism of action involving VZV thymidine kinase (TK)-mediated phosphorylation. Similarly, the replacement of the 3′-OH with chlorine showed a decrease of antiviral activity, which can be correlated to the lack of interaction with VZV TK as demonstrated by enzyme assays. These results confirm free 5′-OH and 3′-OH as necessary requirements for efficient recognition by VZV TK and for potent anti-VZV activity in cell culture. less effort has been made regarding modifications on the sugar moiety. Compared with the parent alkyl compound ([1], R=C 10 , EC 50 =0.015 µM), a decrease in activity of 10 000 times has been observed (McGuigan et al., 2001) when the 3′-OH is protected with a methoxy group. This may indicate little tolerance toward modifications at the 3′-position, which must be further investigated. Moreover, the replacement of the 3′-OH by hydrogen in the parent compound [1] to form the 2′,3′-dideoxy derivative led to a complete loss of antiviral activity versus VZV; surprisingly it led to in vitro activity against human cytomegalovirus (HCMV) at ~1 µM with cytotoxicity above 200 µM (McGuigan et al., 2004) . Initial biological investigation (antiviral time addition studies) on this new series of sugar-modified BCNAs indicated a possible anti-HCMV activity via a novel non-nucleoside mechanism (McGuigan et al., 2004) . Therefore, while a 'conventional' nucleoside mechanism would involve 5′-phosphorylation and subsequent interaction of the triphosphate active form with the viral DNA polymerase, the finding of this novel mechanism of action prompted the design of new series of anti-HCMV compounds, characterized by the presence of the bicyclic base in their structure linked to a non-or highly modified sugar moiety.
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In this context, we planned the synthesis of further series of sugar-modified analogues of BCNAs and we present herein the synthesis and biological evaluation of some 3′-and 5′-chloro derivatives and 5′-deoxygenated derivatives as anti-VZV and/or anti-HCMV agents ( Figure 2 ). We intended to investigate the effects of a chlorinated sugar moiety on antiviral activity, taking into account that chlorine has electronegativity intermediate between hydrogen and oxygen. Moreover, a possible loss of activity against VZV for the 5′-modified derivatives, lacking the 5′-OH group necessary for phosphorylation, would have been further proof of a mechanism of action involving a TK-mediated phosphorylation, while this series could have been of interest in investigating the effect of 5′-modifications on anti-HCMV activity.
Materials and methods

Chemistry
For thin-layer chromatography, precoated, aluminiumbacked plates (60 F-54, 0.2 mm thickness; supplied by E Merck AG, Darmstad, Germany) were used and were developed by ascending method. After solvent evaporation, compounds were detecting by quenching of the fluorescence at 254 nm or 366 nm, upon irradiation with a UV lamp.
Glass columns were slurry-packed in the appropriate eluent under pressure with silica gel, 60A, 40-60 µm, (Phase Separations Ltd, Deeside, Clwyd, UK). Samples were applied as a concentrated solution in the same eluent or pre-adsorbed on silica gel. Fractions containing the product were identified by TLC, pooled and the solvent removed in vacuo.
1 H, 13 C NMR spectra were recorded on a Bruker Avance DPX300 spectrometer (300 MHz and 75 MHz, respectively) (Bruker Instruments, Inc., Billerica, Mass., USA) and autocalibrated to the deuterated solvent reference peak. All 13 C NMR were proton-decoupled.
The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), qu (quartet), q (quintet), m (multiplet), bs (broad signal), dd (double doublet) and dt (double triplet).
Low-resolution mass spectra were run on a VG Biotech Platform II (VG Biotech, Fison Instruments, Altrincham, UK (atmospheric pressure ionization, electrospray mass spectrometry) in either negative or positive mode.
Mass spectra were performed by the service at the University of Birmingham, UK. The solvents used were anhydrous and used as purchased from Aldrich. All glass- ware was oven dried at 130°C for several hours and allowed to cool under a stream of dry nitrogen.
General procedure for the preparation of BCNAs described for 3-
To a stirred solution of 5-iodo-2′-deoxyuridine (6 g, 16.9 mol) in anhydrous dimethylformamide (50 ml) at room temperature and under nitrogen atmosphere, diisopropylethylamine (6 ml, 33.8 mmol), 4-n-pentylphenylacetylene (213.4 mg, 42.3 mmol), tetrakis (triphenyl-phosphine)palladium (0) (1.96 g, 1.69 mmol) and copper (I) iodide (0.64 g, 3.38 mmol) were added. The reaction mixture was stirred for 15 h, after which time Et 3 N (60 ml) and CuI (0.64 g) were added and the reaction mixture was then heated at 80˚C. After 4 h, the solvent was removed in high vacuo and the resulting residue was dissolved in dichloromethane/ methanol (1:1); an excess of Amberlite IRA-400 (HCO 3 form) was added and the mixture stirred at room temperature for 30 min. The reaction mixture was then filtered and washed with methanol and the combined filtrate was evaporated to dryness. The crude residue was purified by flash column chromatography (EtOAc and EtOAc:MeOH= 8:2).The recovered product was crystallized with MeOH to yield the product as a white solid (3.52 g, 52% .6 (C-5′), 71.8 (C-3′), 83.4, 86.4 (C-1′, C-4′), 100.4 (C-5), 107.4 (C-4a), 125.4, 131.8 (C-Ph), 127.4 (ipso-C), 138.5 (C-4), 141.3 (para-C), 154.6 (C-6), 161.1 (C-2), 170.9 (C-7a).
1-[2-Deoxy
. A mixture of 5-iodo-2′-deoxyuridine (4 g, 11.3 mmol) and triphenylmethyl chloride (3.79 g, 13.6 mmol) in anhydrous pyridine (60 ml) was refluxed for 3 h. After that time, the mixture was allowed to cool to room temperature, methanesulphonyl chloride (2.6 ml, 39.0 mmol) was added to the ice-cooled solution and the reaction mixture was stirred for 3 h at room temperature. The solvent was evaporated under vacuum and the residue was dissolved in DCM. The solution was quickly washed with HCl 1M and a saturated aqueous solution of NaCl. The organic phase was dried over MgSO 4 and the solvent was removed under vacuum. The crude was directly used for the following reaction without further purification.
(1.90 g, 2.82 mmol) was dissolved in hot EtOH (200 ml) and sodium hydroxide was added (112.8 mg, 2.82 mmol); refluxing was continued for 2 h. The product precipitated from the reaction mixture as a white solid after the reaction was allowed to reach room temperature. After filtration and washing with MeOH the filtrate was recovered, concentrated then extracted with chloroform from a saturated aqueous solution of NaCl. The organic phase was dried on MgSO 4 , filtered, and the solvent was evaporated. The residue was purified by flash column chromatography (CHCl 3 :MeOH=95:5 and Et 3 N 0.1%), washed with MeOH and combined with the previous recovered solid to yield the product as white solid (0.90 g, 44%). 
1-[2,3-Dideoxy
(6.00 g, 10.63 mmol) and anhydrous pyridine hydrochloride (4.91 g, 42.52 mmol) in dimethyl formamide (DMF) dry (60 ml) was stirred under argon atmosphere for 3 days. The solvent was then evaporated and the residue was dissolved in chloroform and washed with a saturated solution of NaHCO 3 and an aqueous solution of NaCl. The organic phase was dried over MgSO 4 and the solvent was removed under vacuum. The crude was purified by flash column chromatography (EtOAc:Pet. Ether=1:1) to yield the product as a white solid (4.19 g, 64%). The corresponding deprotected derivativative 1-(2,3-dideoxy-3-chloro-β-D-ribofuranosyl)-5iodouracil [6] was also isolated (0.77 g, 19%). 
1-(2,3-Dideoxy-3-chloro-β-D-ribofuranosyl)-5-iodouracil
[6]. A solution of [8] (0.5 g, 0.8 mmol) in aqueous acetic acid (80%, 20 ml) was heated at 90°C for 3 h. Then the solvent was evaporated and the residue was purified by flash column chromatography (DCM and DCM:MeOH=95:5). The recovered product was finally washed with DCM to yield the product as a white solid (133.5 mg, 44%). 1 H-nmr (DMSO-d 6 ; 300 MHz) δ 11.73 (1H, bs, NH), 8.39 (1H, s, H-6), 6.0 (1H, dd, J=6.0 Hz, H-1′), 5.76 (1H, bs, 5′-OH), 5.39-4.57 (1H, m, H-3′), 4.10-4.07 (1H, m, H-4′), 3.71-3.36 (2H, m, H-5′), 2.71-2.62 (1H, m, H-2′ b ), 2.52-2.44 (1H, m, H-2′ a ). 13 C-nmr (DMSO-d 6 ; 75 MHz) δ 41.1 (C-2′), 55.7 (C-3′), 60.1 (C-5′), 69.9 (C-5), 84.6 (C-1′), 87.9 (C-4′), 145.2 (C-6), 150.4 (C-2), 160.9 (C-4). 22.4, 26.7, 27.7, 28.7, 28 .7, (5×CH 2 ), 28.9 (β-CH 2 ), 31.6 (α-CH 2 ), 42.1 (C-2′), 55.1 (C-3′), 59.9 (C-5′), 87.1, 88.6 (C-1′, C-4′), 100.1 (C-5), 106.8 (C-4a), 137.1 (C-4), 154.1 (C-2), 158.8 (C-6), 171.6 (C7a 
3-(2,3-Dideoxy
-3-chloro-β-D-ribofuranosyl)-6-octyl- 2,3-dihydrofuro[2,3-d]pyrimidin-2-one [5a].
. This was prepared as described for [11b] starting from [6] (450.0 mg, 1.21 mmol) in anhydrous DMF (8 ml), using diisopropylethylamine (0.42 ml, 2.4 mmol), 4-npentylphenylacetylene (0.59 ml, 3.02 mmol), tetrakis(triphenylphosphine)palladium (0) (139.8 mg, 0.12 mmol) and copper (I) iodide (46.0 mg, 0.24 mmol). For the cyclization step, Et 3 N (5 ml) and CuI (46.0 mg) were used to yield the product as a white solid (68.7 mg, 23%). 3- (2, pyrimidin-2-one [3a] . This was prepared as described for [11b] starting from [10] (650.0 mg, 1.75 mmol) in anhydrous DMF (15 ml), using diisopropylethylamine (0.61 ml, 3.49 mmol), 1-decyne (0.79 ml, 4.36 mmol), tetrakis(triphenylphosphine)palladium (0) (202.2 mg, 0.175 mmol) and copper (I) iodide (66.5 mg, 0.349 mmol). For the cyclization step, Et 3 N (6 ml) and CuI (66.5 mg) were used to yield the product as a white solid (296.6 mg, 45%). 
3-(2-Deoxy
. This was prepared as described for [11b] starting from 5-iodo-2′-deoxyuridine (4 g, 0.011 mol) in dry DMF (40 ml), using diisopropylethylamine (3.9 ml), 1-decyne (4.6 ml), tetrakis(triphenylphosphine)palladium (0) (1.31 g) and copper (I) iodide (0.43 g). For the cyclization, Et 3 N (10 ml) and CuI (0.43 g) were used to yield the product as a white solid (2.22 g, 54%). 1 H-nmr (DMSO-d 6 ; 300 MHz) δ 8.64 (1H, s, H-4), 6.44 (1H, s, H-5), 6.17 (1H, dd, J=6.1 Hz, H-1′), 5.29 (1H, d, J=4.0 Hz, 3′-OH), 5.13 (1H, t, J=5.01 Hz, 5′-OH), 4.24 (1H, m, H-3′), 3.93-3.90 (1H, m, H-4′), 3.70-3.60 (2H, m, H-5′), 2.65 (2H, t, J=7.31 Hz, α-CH 2 ), 2.43-2.34 and 2.09-2.01 (2H, m, H-2′), 1.64-1.60 (2H, m, β-CH 2 ),1.30-1.26 (10H, m, 5×CH 2 ), 0.84 (3H, t, CH 3 ).
3-[2,5-Dideoxy
. This was prepared as described for [12b] starting from [10] (800.0 mg, 2.19 mmol), in anhydrous DMF (15 ml), using dimethylformamide dineopentylacetal (1.2 ml) and 2-mercaptopyrimidine (307.7 mg). After purification by flash column chromatography (EtOAc), NMR showed the presence of starting material, so this mixture was reacted again using the same conditions. The subsequent flash column chromatography conducted in EtOAc yielded the product as a white solid (803.7 mg, 80%). 1 H-nmr (DMSO-d 6 ; 300 MHz) δ 8.68 (2H, d, J=4.9 Hz, H-4pyrim, H-6pyrim), 8.46 (1H, s, H-4), 7.27 (1H, t, J=4.9, H-5pyrim), 6.45 (1H, s, H-5), 6.17 (1H, dd, J=6.3 Hz, H-1′), 5.47 (1H, d, J=4.0 Hz, 3′-OH), 5.30-5.13 (1H, m, H-3′), 4.23-4.12 (1H, m, H-4′), 3.61-3.41 (2H, m, H-5′), 2.66 (2H, t, J=7.2 Hz, α-CH 2 ), 2.46-2.34 and 2.17-2.02 (2H, m, H-2′), 1.64-1.59 (2H, m, β-CH 2 ), 1.30-1.25 (10H, m, 5×CH 2 ), 0.86 (3H, t, CH 3 ). 13 C-nmr (DMSO-d 6 ; 75 MHz) δ 14.3 (CH 3 ), 22.4, 26.7, 27.7, 28.7, 28.9, 29.0, 31.6, 32.6, 40 .4 (7×CH 2 , C-2′, C-5′), 72.9 (C-3′), 86.0, 88.2 (C-1′, C-4′), 100.2 (C-5), 107.0 (C-4a), 117.9 (C-5pyrim), 136.9 (C-4), 154.1, 158.0, 158.3, 158 .7 (C-4pyrim, C-6pyrim, C-6, C-2), 170.6, 171.6 (C-2pyrim, C-7a).
3- [2, 3d] pyrimidin-2-one [12b] . To a stirred solution of [11b] (900.0 mg, 2.26 mmol) in anhydrous DMF (20 ml) under nitrogen atmosphere, dimethylformamide dineopentylacetal (2.2 ml) and 2-mercaptopyrimidine (506.9 mg) were added and the reaction was refluxed for 4 h. Then dimethylformamide dineopentylacetal (1.1 ml) and 2mercaptopyrimidine (250 mg) were added again, in order to react the remaining starting material. After 4 h refluxing, the solvent was removed in high vacuo and the crude product was purified by flash column chromatography (CHCl 3 :MeOH=95:5). The appropriate fractions were combined and the solvent was removed in high vacuo and the product was crystallized with MeOH to yield the product as a white solid (494.5 mg, 44%). 3, 30.8, 31.2, 32.6, 35.3, 40 .7 (4×CH 2 , C-2′, C-5′), 72.9 (C-3′), 86.1, 88.4 (C-1′, C-4′), 99.1 (C-5), 107.6 (C-4a), 117.9 (C-5pyrim), 124.9, 129.4 (C-Ph), 126.2 (ipso-C), 138.0 (C-4), 144.5 (para-C), 154.1, 154.3 (C-6, C-2), 158.3 (C-4pyrim, C-6pyrim), 170.6, 171.5 (C-2pyrim, C-7a).
3- (2, 19.8, 23.1, 27.2, 28.7, 29.4, 29.6, 29.6, 32.2, (7×CH 2 3-(2,5-dideoxy-β-D-ribofuranosyl)-6-(4-n-pentylphenyl)-2,3-dihydrofuro[2,3-d] pyrimidin-2-one [4b] . Under argon atmosphere [12b] (540.0 mg) was stirred in MeOH (25 ml), catalytic Ra-Ni was added and the reaction was refluxed for 30 mins. The catalyst was filtered off through celite and the filtrate was evaporated to dryness. The residue was purified by flash column chromatography (CHCl 3 :MeOH=95:5). The product was crystallized with MeOH to yield the product as a white solid (102.7 mg, 25%). 
Biology
Virology Cells. Human embryonic lung (HEL) fibroblasts and E6SM cells were grown in minimum essential medium (MEM) supplemented with 10% inactivated fetal calf serum (FCS), 2 mM L-glutamine and 0.3% sodium bicarbonate.
Viruses. The laboratory wild-type VZV strains OKA and YS, the TK-deficient VZV strains 07-1 and YS-R, HSV-1 (KOS), HSV-2 (G), the thymidine kinase-deficient HSV-1 strains B-2006 and VMW 1837, human cytomegalovirus (HCMV) strains Davis and AD-169, and vaccinia virus were used in the virus inhibition assays. Antiviral assays. Confluent HEL cells grown in 96-well microtitre plates were inoculated with VZV at an input of 20 PFU (plaque forming units) per well, or with HCMV at an input of 100 PFU per well with HSV at 100 CCID 50 (50% cell culture infective doses) per well. After a 1 to 2-h incubation period, residual virus was removed and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 2 mM L-glutamine and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days (VZV) or virusinduced cytopathicity HCMV after 7 days and HSV, VV after 3 days) by 50% compared with the untreated control.
Cytotoxicity assays. Confluent monolayers of HEL cells as well as growing HEL cells in 96-well microtitre plates were treated with different concentrations of the experimental drugs. Cell cultures were incubated for 3 (growing cells) or 5 (confluent cells) days. After 3 days, the cells were trypsinized and the cell number was determined using a Coulter counter.
The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%. After 5 days, a morphological alteration visible under the microscope was recorded (MCC).
VZV TK affinity assay. The radiolabelled nucleoside [CH 3 -3 H]dThd (specific radioactivity, 52 Ci/mmol) was obtained from the Radiochemical Centre (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK).
VZV TK was expressed in Escherichia coli as a glutatione-S-transferase (GST) fusion protein, according to the already published procedure (Sienaert et al., 2002) .
The IC 50 of the test compounds against phosphorylation of [CH 3 -3 H]dThd as the natural substrate by VZV TK was determined under the following reaction conditions: the standard reaction mixture (50 ml) contained 50 mM Tris-HCl, pH 8.0, 2.5 mM MgCl 2 , 10 mM dithiothreitol, 2.5 mM ATP, 10 mM NaF, 1.0 mg/ml bovine serum albumin, 1 µM [CH 3 -3 H]dThd (0.1 µCi) and an appropriate amount of test compound. The reaction was started by the addition of enzyme and then incubated at 37°C for 30 min; the reaction was terminated by spotting an aliquot of 45 µl onto DE-81 discs (Whatman, Maidstone, UK). After 15 min, the discs were washed three times for 5 min each in 1 mM HCOONH 4 while shaking, followed by 5 min in ethanol (70%). Finally, the filters were dried and assayed for radioactivity in a toluene-based scintillant. The IC 50 was defined as the drug concentration required to inhibit thymidine phosphorylation by 50%.
3′-Modified VZVs
Results 5-Iodo-2′,3′-dideoxy-3′-chlorouridine [6] is the synthon required for the Pd-catalysed coupling and copper-catalysed cyclization involved in the well-established procedure for the synthesis of bicyclic furanopyrimidines. As previously reported in the literature (Verheyden et al., 1972) , the key step in the synthesis is the opening of the anhydronucleoside [7]. This is carried out using four equivalents of pyridine hydrochloride, providing the desired chloro nucleoside [8] in 64% yield together with a slight amount (19%) of the deprotected nucleoside [6] (Figure 3) .
According to the published procedure (Horwitz, 1962) , the synthesis of the anhydronucleoside involved a selective 5′-tritylation followed by treatment with mesyl chloride to afford [9], which was used in the subsequent step without further purification. This protected nucleoside [9] was then treated with 1 equivalent of sodium hydroxide in ethanolic solution providing [7] in 44% yield from idoxuridine (IDU).
The target synthon [6] was finally achieved by deprotection with AcOH in 44% yield.
The successful introduction of a chlorine atom was demonstrated by mass spectrometry: the two isotopic peaks were found in ES + at 639.3 and 637.2. Moreover, the exact assignment of the 1 H-NMR was made on the basis of a COSY experiment. Then a NOESY experiment confirmed the alpha configuration of the chlorine showing cross-peaks between H-1′ and H-2′ alpha and between H-2′ beta and H-3′ (data not shown).
Compound [6] was then coupled and cyclized following the standard procedure used in our laboratories (McGuigan et al., 1999) affording derivatives [5a] and [5b] in 35% and 23% overall yield, respectively. The synthesis of the key synthon 5-iodo-2′,5′-dideoxy-5′chlorouridine for the 5′-chlorinated derivatives was accomplished by following the previously published procedure (Verheyden et al., 1972) Finally, the 5′-deoxygenation was attempted directly on the cyclized derivatives (Figure 4) . According to the literature (Holÿ, 1972) , the selective 5′-derivatization in the presence of dimethylformamide dineopentylacetal and 2mercaptopyrimidine was achieved in 80% and 44% yields for the octyl [11a] and pentylphenyl [11b] derivatives, respectively. Then the treatment with Ra-Ni in methanol afforded the deoxygenated derivatives [4a] and [4b] in 25% yield for the two compounds.
The disappearance of the 5′-OH in the 1 H-NMR of [4a] and [4b] as well with the presence of a doublet for the H-5′ at 1.39 ppm and 1.36 ppm, respectively, supported that the deoxygenation had taken place.
Discussion
The synthesized nucleoside derivatives were evaluated for their ability to inhibit the replication of VZV in human embryonic lung (HEL) cells. 
3′-Modified VZVs
activity can be seen as a further evidence of a mechanism of anti-VZV action involving an obligate 5′-phosphorylation. The biological data indicate that the replacement of 3′-OH with a chlorine atom is also detrimental for the potency, with a decrease in biological activity of at least 1800-fold for [5a]. This confirms the poor tolerance for substituents other than 3′-OH, also noticed in the case of the 3′-OMe analogue and for the 2′,3′-dideoxy derivative. It appears that the free 3′-OH is obligatory for the activity of BCNAs against VZV, but in contrast to the 5′-OH, its role has still to be fully investigated.
In order to further explore the effects of the 3′ modifications in the BCNAs, the synthesized 3′-chloro derivatives [5a-5b] were tested for VZV TK inhibition in comparison with [11a-11b] . The results showed that [5a-5b] do not inhibit the phosphorylation of dThd by VZV TK, while [11a] and [11b] inhibited it at 34 µM and 4.0 µM, respectively.
This lack of inhibitory activity for VZV TK, which may imply a lack of substrate activity, is most likely the origin of the loss of antiviral activity related to [5a-5b]. As a plausible reason for this result, the loss of the OH hydrogen bond donor and/or the atomic size of the chlorine, should be taken into consideration.
On the basis of this result it can be deduced that the 3′-OH is a necessary requirement for anti-VZV activity, one possible reason being a lack of VZV TK-mediated phosphorylation.
The derivatives were also tested against HCMV without displaying any significant activity (data not shown). This indicates the dideoxysugar moiety or similar to be required for anti-HCMV activity. Also, no appreciable anti-HSV or vaccinia virus activity was found. An extensive study aimed at further exploring alternative modifications on the sugar moiety of BCNAs is currently ongoing in our laboratories.
